Sionna Therapeutics to Participate in Upcoming November Investor Conferences
Sionna Therapeutics (Nasdaq: SION) announced management will participate in investor fireside chats at two November 2025 conferences: Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025 at 8:30 a.m. ET and Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 8:00 a.m. ET. Live webcasts will be available on the company’s Investors "Events" page and replays will be posted following each event. The company is a clinical-stage biopharmaceutical developer focused on novel medicines that normalize CFTR function for cystic fibrosis.
Sionna Therapeutics (Nasdaq: SION) ha annunciato che la direzione parteciperà a colloqui informativi per investitori in due conferenze di novembre 2025: Guggenheim 2nd Annual Healthcare Innovation Conference il martedì 11 novembre 2025 alle 8:30 ora dell'Est e Stifel 2025 Healthcare Conference il mercoledì 12 novembre 2025 alle 8:00 ora dell'Est. Le dirette web continueranno sul sito degli investitori dell'azienda nella pagina "Events" e le registrazioni saranno pubblicate dopo ogni evento. L'azienda è uno sviluppatore biofarmaceutico in fase clinica focalizzato su medicinali innovativi che normalizzano la funzione CFTR per la fibrosi cistica.
Sionna Therapeutics (Nasdaq: SION) anunció que la dirección participará en conversaciones informales para inversionistas en dos conferencias de noviembre de 2025: Conferencia de Innovación en Salud anual 2 de Guggenheim el martes 11 de noviembre de 2025 a las 8:30 a.m. ET y Conferencia de Salud 2025 de Stifel el miércoles 12 de noviembre de 2025 a las 8:00 a.m. ET. Se transmitirán en vivo por internet y las repeticiones se publicarán tras cada evento. La empresa es un desarrollador biofarmacéutico en etapa clínica centrado en medicamentos novedosos que normalizan la función CFTR para la fibrosis quística.
Sionna Therapeutics (나스닥: SION)은 경영진이 2025년 11월 두 차례에 걸친 투자자 질의응답 대담에 참여할 것이라고 발표했습니다: 구겐하임 2nd Annual Healthcare Innovation Conference가 2025년 11월 11일 화요일 오전 8:30(동부시간)과 Stifel 2025 Healthcare Conference가 2025년 11월 12일 수요일 오전 8:00(동부시간)에 열립니다. 생중계는 회사의 투자자 페이지의 'Events'에서 시청할 수 있으며 각 행사 후에 다시보기가 게시됩니다. 이 회사는 임상단계 생물의약품 개발자로, 섬유화증 치료를 위한 CFTR 기능을 정상화하는 신규 의약품에 초점을 맞추고 있습니다.
Sionna Therapeutics (Nasdaq : SION) a annoncé que la direction participera à des entretiens informels pour investisseurs lors de deux conférences de novembre 2025 : Guggenheim 2e conférence annuelle sur l'innovation en soins le mardi 11 novembre 2025 à 8h30 HNE et la Conférence sur les soins de Stifel 2025 le mercredi 12 novembre 2025 à 8h00 HNE. Les diffusions en direct seront disponibles sur la page « Événements » des investisseurs de la société et les rediffusions seront publiées après chaque événement. L'entreprise est un développeur biopharmaceutique en phase clinique axé sur des médicaments novateurs qui normalisent la fonction CFTR pour la fibrose kystique.
Sionna Therapeutics (Nasdaq: SION) gab bekannt, dass das Management an Investorensprechstunden bei zwei Konferenzen im November 2025 teilnehmen wird: Guggenheim 2nd Annual Healthcare Innovation Conference am Dienstag, 11. November 2025, 8:30 Uhr ET und Stifel 2025 Healthcare Conference am Mittwoch, 12. November 2025, 8:00 Uhr ET. Live-Webcasts sind auf der Investorenseite der Firma unter der Rubrik „Events“ verfügbar, und die Wiederholungen werden nach jeder Veranstaltung veröffentlicht. Das Unternehmen ist ein klinisch-phasenweiser Biopharmaentwickler, der sich auf neuartige Arzneimittel konzentriert, die die CFTR-Funktion bei Mukoviszidose normalisieren.
سيوانا ثيرابيوتيكس (ناسداك: SION) أعلنت أن الإدارة ستشارك في محادثات المستثمرين في مؤتمرين في نوفمبر 2025: معرض جوجنهايم الثاني للابتكار في الرعاية الصحية في الثلاثاء 11 نوفمبر 2025 الساعة 8:30 صباحًا بتوقيت شرق الولايات المتحدة و مؤتمر ستايفل للرعاية الصحية 2025 في الأربعاء 12 نوفمبر 2025 الساعة 8:00 صباحًا بتوقيت شرق الولايات المتحدة. ستكون البثوث الحية متاحة على صفحة 'Events' للمستثمرين في الشركة، وستُنشر إعادة التشغيل بعد كل حدث. الشركة مطوِّر أدوية حيويّة في مرحلة سريرية يركّز على أدوية جديدة تعيد وظيفة CFTR لمرض التليّف الكيسي.
- None.
- None.
WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events:
- Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11th, 2025, at 8:30 a.m. ET; and
- Stifel 2025 Healthcare Conference on Wednesday, November 12th, 2025, at 8:00 a.m. ET
Live webcasts of the presentations will be available under the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. Replays will also be available following the events.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Media Contact
Adam Daley
CG Life
212.253.8881
adaley@cglife.com
Investor Contact
Juliet Labadorf
ir@sionnatx.com
FAQ
When will Sionna Therapeutics (SION) present at the Guggenheim Healthcare Innovation Conference?
When is Sionna Therapeutics (SION) scheduled to speak at the Stifel 2025 Healthcare Conference?
Where can investors watch the Sionna (SION) conference presentations live and after the events?
What topics will Sionna Therapeutics (SION) likely cover in the November 2025 investor fireside chats?
Will recordings of Sionna’s (SION) November 2025 presentations be available after the conferences?
